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Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma
(BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD)
regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients  20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma
were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this 
study. Eligible patients’ case report forms were requested from their physicians to obtain
clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were 
analyzed, none of which were infected with human immunodeficiency virus. The majority of
patients had advanced diseases, and 24 patients achieved a complete response (75.0%).
After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates
were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the
R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin,
vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less
than 25% of patients received greater than 80% of the planned dose of each drug. Poor
performance status was related to the lower RDIs of doxorubicin and methotrexate. 
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for 
dose-intense chemotherapy. However, management of patients who are intolerant to a
dose-intense regimen remains problematic due to the frequent occurrence of treatment-
related complications.
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Introduction
Burkitt lymphoma (BL) is a highly aggressive B-cell 
lymphoma accounting for 1%-5% of all non-Hodgkin 
lymphomas (NHL) in adults [1,2]. BL was first identified as
a childhood endemic tumor with a geographical distribution
[3]. Since then, worldwide and sporadic occurrence of BL has
been reported, and BL has become a well-known human 
immunodeficiency virus (HIV)–associated malignancy [3].
As BL tumor cells are characterized by rapid cellular growth,
conventional regimens for NHL have shown disappointing
results [4]. On the other hand, dose-intense, multi-fraction-
ated chemotherapeutic regimens have been shown to 
improve treatment outcomes [5-7]. A recent population-
based study [8] demonstrated the impact of regimen 
intensity on treatment outcome of adult BL patients, 
reporting a 2-year overall survival (OS) rate of only 38.8% for
cyclophosphamide, adriamycin, vincristine, and prednisone
(CHOP) or CHOP-like regimens, whereas survival rates of
68.6% to 82.8% were achieved for dose-intense regimens. 
In addition to BL, other lymphomas morphologically 
resembling BL were classified as “atypical BL/Burkitt-like
lymphoma” by the 2001 World Health Organization (WHO)
classification, and these morphologically similar lymphomas
are thought to lie on a continuum between BL and diffuse
large B-cell lymphoma (DLBCL) [9]. In the 2008 WHO 
classfication, classification of these atypical BL/Burkitt-like
lymphomas was more refined, including a new provisional
entity, “B-cell lymphoma, unclassifiable, with features 
intermediate between BL and DLBCL,” which we define as
BL-U in this report [9]. Despite these changes in classifica-
tion, there are no established treatment guidelines for these
lymphomas. Thus, dose-intense treatment strategies similar
to those used for BL are typically used for aggressive 
lymphomas with overlapping features of BL and DLBCL
[10].
Among dose-intense treatment regimens, hyper-CVAD
regimen (hyper-fractionated cyclophosphamide, adriamycin,
vincristine, and dexamethasone alternated with methotrex-
ate plus cytarabine) has been proposed for treatment of
highly aggressive lymphoid malignancies by the MD 
Anderson Cancer Center [6]. 
Since addition of rituximab to hyper-CVAD regimen (R-
hyper-CVAD) has been shown to improve treatment 
outcomes [11], R-hyper-CVAD has been used as a primary
treatment option for BL. Using this approach, a complete 
remission (CR) rate of 86% and 3-year OS rate of 89% without
any induction death were observed [11]. However, 
significant toxicity, delayed treatment, and treatment-related
early death are not uncommon in actual clinical practice since
patient characteristics often differ from those in clinical trials.
As elderly and frail patients are commonly treated in clinical
practice, information on real-life outcomes of the regimen
could be a useful reference for physicians who treat BL. In
addition, although ethnic differences might affect drug 
tolerability and efficacy, outcomes of R-hyper-CVAD in
Asian patients have never been reported. Thus, we analyzed
the outcomes of adult Korean patients with sporadic BL or
BL-U treated with R-hyper-CVAD regimen [11] by focusing
on tolerability and delivered dose intensity.
Materials and Methods
1. Patients
We reviewed the medical records of 14 hospitals belonging
to the Consortium for Improving Survival of Lymphoma
(CISL) [12] and selected patients who fulfilled the following
inclusion criteria: 1) age  20 years, 2) pathologically diag-
nosed as BL or BL-U according to the 2008 WHO criteria, and
3) treated with at least one cycle of R-hyper-CVAD as the
first-line systemic treatment. The Institutional Review Boards
of each participating center approved this study and 
waived informed consent since no actual intervention was
performed due to its retrospective nature.
2. Case report forms
Case report forms (CRF) for eligible patients were 
requested from physicians who treated the patients in this
retrospective study (CISL-1201) from March 2012 to March
2013. The CRF contained a fill-in section on patient 
characteristics such as gender, age at diagnosis, anti-HIV 
antibody status, the International Prognostic Index (IPI) 
factors, bone marrow involvement, and crucial laboratory
data, including complete blood cell counts and serum lactate
dehydrogenase, among other values. Patient height, weight,
accurate dose of each administered drug, and date of drug
administration were obtained in order to calculate relative
dose intensity (RDI). Hematologic toxicity and grade 3 or
greater non-hematologic toxicity was reviewed for each cycle
in the CRF. Special events during immunochemotherapy,
such as tumor lysis syndrome, cerebellar ataxia due to 
cytarabine, and infectious episodes, were investigated in 
detail. The results of the interim and final treatments 
according to the revised response criteria for malignant 
lymphomas [13] were collected along with data on relapse,
progression, or death of patients. 
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3. Statistical analysis
Event-free survival (EFS) denotes survival free from 
progressive disease or discontinuation of therapy for any 
reason. To eliminate the impact of early death on overall
treatment outcomes, we also used disease-free survival
(DFS), which is the same parameter as EFS except that death
by any cause other than progression of lymphoma is not 
considered. OS denotes survival free from death by any
cause. The Kaplan-Meier method and log-rank test were
used for survival analysis. Univariate and multivariate
analyses were performed by using a backward Cox regres-
sion model with variables of p < 0.1 in the univariate 
analysis. Mann-Whitney tests were used to compare means
between the two groups. All values were two-sided, and 
statistical significance was accepted at a level of p < 0.05.
Results
1. Patient characteristics
Data on 43 patients from 14 medical centers were collected
and analyzed. All patients had sporadic BL or BL-U (i.e., no
patients had HIV-associated lymphoma) and were of a 
median age of 51 years. Dates of initial diagnosis ranged
from February 2006 to March 2013, and the majority of 
patients had advanced diseases at the time of diagnosis.
More than half of patients were in Ann Arbor stage IV (n=29,
67.4%), had two or more extranodal sites (n=23, 53.5%), 
and were at high or high-intermediate risk (n=25, 58.1%) 
according to the standard IPI. A summary of patients’ 
characteristics is shown in Table 1.
2. Treatment and tumor response
Prophylactic measures, doses and intervals of cytotoxic
drugs, number of planned cycles, central nervous system
(CNS) prophylaxis, and overall schedule of the regimen were
as those in a previous study [11], except for administration
of rituximab (two patients received 375 mg/m2 of rituximab
on the first and eighth days of each cycle, whereas others 
received the same dose of rituximab on the first day of each
cycle only). According to the recommendations of the Korean
National Health Insurance Guideline, granulocyte-colony
stimulating factor (G-CSF) was administered daily starting
the first day patients showed an absolute neutrophil count
(ANC) < 1,000/µL until the third consecutive day patients
showed an ANC > 3,000/µL in each cycle. Of the 32 
evaluable patients, 24 patients (75%) achieved a CR, and six
patients experienced disease progression in the final 
response evaluation (Table 2).
3. Survival analysis
Seven patients experienced relapse after CR, with two 
patients experiencing CNS involvement and five showing
extra-CNS sites (two patients with skin and subcutaneous
nodules, two patients with bone marrow involvement, and
one patient with right inguinal lymph node involvement).
After a median follow-up period of 20.0 months, the 2-year
DFS, EFS, and OS rates of patients were 78.6%, 70.9%, and
81.4%, respectively (Fig. 1). According to univariate analysis,
bone marrow involvement, an absolute lymphocyte count
(ALC) < 1,200/µL, and being a member of the standard IPI-
defined high-risk group were all associated with poorer EFS.
Among IPI factors, age > 60 years and a poor Eastern 
Cooperative Oncology Group performance status (ECOG PS)
contributed to lower EFS, whereas more than one extranodal
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Table 1. Patient characteristics
Parameter No. (%) (n=43)
Gender
Male 29 (67.4)
Age (yr)
Median (range) 51 (20-83)
20-40 14 (32.6)
41-60 17 (39.5)
> 60 12 (27.9)
Ann Arbor stage
I 3 (7.0)
II 7 (16.3)
III 4 (9.3)
IV 29 (67.4)
ECOG performance status
 2 13 (30.2)
 3 4 (9.3)
Lactate dehydrogenase
Elevated 32 (74.4)
Extranodal lesion
 2 sites 23 (53.5)
Standard international 
prognostic index
Low risk 9 (20.9)
Low-intermediate risk 9 (20.9)
High-intermediate risk 12 (27.9)
High risk 13 (30.2)
B Symptoms
Present 16 (37.2)
Bone marrow involvement
Involved 9 (20.9)
Bulky lesion
Present 10 (23.3)
ECOG, Eastern Cooperative Oncology Group.
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Table 2. Results of interim and final response evaluations according to the revised criteria
Interim Final
Complete response 26 24
Partial response 7 1
Stable disease 2 1
Progressive disease 1 6
Not evaluable (NE) 7 11
Causes of NE Six early deaths Seven patients NE in the interim response evaluation
One discontinuation of therapy due to Three discontinuations of therapy due to 
intolerant toxicity and impaired intolerant toxicity and impaired PS
performance status (PS) One could not complete the treatment schedule due to 
delayed marrow recovery
Table 3. Univariate and multivariate analyses of event-free survival in the 43 patients
Parameter
For event-free survival For disease-free survival
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Univariate analysis
High risk by standard IPI 5.7 2.0-16.4 0.001 2.9 0.8-10.6 0.1
Age > 60 yr 3.1 1.1-8.5 0.034 1.7 0.4-6.6 0.452
> 1 extranodal site 2.0 0.7-5.9 0.208 1.5 0.4-5.4 0.525
Elevated serum lactate 1.5 0.4-5.2 0.553 0.9 0.2-3.5 0.872
dehydrogenase
Ann Arbor stage III/IV 2.2 0.5-9.6 0.31 1.4 0.3-6.4 0.706
ECOG PS  2 6.3 2.2-18.1 0.001 3.2 0.9-11.7 0.073
Age > 40 yr 3.5 0.8-15.6 0.101 2.3 0.5-11.0 0.294
Bulky lesion 0.8 0.2-3.0 0.786 0.8 0.2-4.0 0.836
B Symptoms 1.6 0.6-4.4 0.652 1.8 0.5-6.1 0.374
Bone marrow involvement 3.4 1.2-9.6 0.021 2.3 0.6-9.0 0.228
Absolute lymphocyte 3.5 1.2-10.2 0.021 2.6 0.7-9.5 0.141
count < 1,200/µL
Multivariate analysis
With individual IPI factors
Age > 60 yr 3.9 1.3-12.1 0.018 For disease-free survival,
ECOG PS  2 7.4 2.4-23.3 0.001 multivariate analysis could not be
Absolute lymphocyte 3.7 1.2-11.4 0.022 performed since most parameters had a p-value of  0.1
count < 1,200/µL
High risk standard IPI as - - -
a single parameter
High risk by standard IPI 5.8 2.0-16.6 0.001
Absolute lymphocyte 3.5 1.2-10.3 0.022
count < 1,200/µL
CI, confidence interval; IPI, International Prognostic Index; ECOG PS, Eastern Cooperative Oncology Group performance 
status.
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site, stage III or IV, and elevated serum lactate dehydroge-
nase levels did not. According to multivariate analysis, ALC
< 1,200/µL and being a member of the high-risk group were
independent risk factors (Table 3). In contrast to the Cox 
regression test for EFS, most parameters did not have an 
impact on DFS (Table 3).
4. Toxicities
Early deaths were reported in cycles 1A (n=2; age, 51 and
64 years, respectively), 1B (n=1; age, 66 years), 2A (n=2; age,
67 and 72 years, respectively), and 2B (n=1; age, 47 years).
Five of them (except for one 47-year-old patient) had an
ECOG PS  2. Causes of treatment-related mortality (TRM)
were bacterial septicemia (n=5) and tumor lysis syndrome
(n=1; age, 51 years). In cycle 1A, four patients (9.3%) experi-
enced tumor lysis syndrome. Two patients recovered from
tumor lysis syndrome with the support of hemodialysis, one
patient recovered with only hydration and oral allopurinol
use, and the other patient died of rapidly progressing tumor
lysis syndrome during preparation for continuous renal 
replacement therapy. Cerebellar ataxia also occurred in four
patients during cycle 1B. All of these patients recovered, but
re-introduction of cytarabine was limited thereafter, and one
patient could not complete R-hyper-CVAD. Most patients
had grade 3 or 4 hematologic toxicity. Of these patients, 34
patients (79.1%) experienced anemia, 42 patients (97.7%) had
neutropenia, and 28 patients (86.0%) had thrombocytopenia.
Eight patients experienced grade 3 or 4 non-hematologic 
toxicity, such as alanine transaminase elevation (n=4), nausea
(n=2), diarrhea (n=1), and rituximab-induced pneumonitis
(n=1). Thirty-nine patients (90.7%) had febrile neutropenia,
and bacterial growth was reported in the blood cultures of
16 patients (41.0%).
5. Dose intensities
The median RDIs of adriamycin, vincristine, methotrexate,
and cytarabine were 64.3%, 65.0%, 66.1%, and 58.9%, 
respectively. Only 10.5% to 23.3% of patients received greater
than 80% of the planned doses of chemotherapeutic agents.
When we analyzed patients according to age (> 40 years vs.
 40 years, or > 60 years vs.  60 years), there were no 
differences in RDIs. However, PS was related to differences
in RDIs of doxorubicin and methotrexate (Table 4). The 
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Fig. 1.  Kaplan-Meier curves of time to progression, 
event-free survival, and overall survival  of the analyzed
patients.
Table 4. Dose intensities of doxorubicin, vincristine, methotrexate, and cytarabine in the analyzed patients
Doxorubicin (n=43) Vincristine (n=43) Methotrexate (n=38) Cytarabine (n=38)
Median RDI (%) 64.3 65 66.1 58.9
Range 35.6-100 38.3-100 36.0-100 28.4-100
100% dose 4 (9.3) 4 (9.3) 1 (2.6) 1 (2.6)
> 90% dose 4 (9.3) 5 (11.6) 1 (2.6) 1 (2.6)
> 80% dose 8 (18.6) 10 (23.3) 4 (10.5) 4 (10.5)
> 70% dose 16 (37.2) 16 (37.2) 14 (36.8) 13 (34.2)
> 60% dose 25 (58.1) 27 (62.8) 24 (36.8) 19 (50.0)
> 50% dose 32 (74.4) 36 (83.7) 29 (76.3) 25 (65.8)
p-value (impact on RDI)
Age (> 40 yr vs.  40 yr) 0.306 0.429 0.314 0.259
Age (> 60 yr vs.  60 yr) 0.384 0.512 0.813 0.566
ECOG PS ( 2 vs. < 2) 0.035 0.165 0.019 0.299
Values are presented as number (%) unless otherwise indicated. RDI, relative dose intensity; ECOG PS, Eastern Cooperative
Oncology Group performance status.
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median number of days required for a complete cycle of 
immunochemotherapy for each patient was 31.0 days (range,
21 to 54.8 days). There was no difference in the number of
days required for a cycle of R-hyper-CVAD among patients
 60 years versus > 60 years old (p=1.000). Patients with an
ECOG PS of  2 tended to have longer cycles compared to
those with a PS of 0 or 1. However, these results were not sta-
tistically significant (p=0.065).
Discussion
In the current study, R-hyper-CVAD showed overall 
treatment outcomes comparable to those of previous 
retrospective and prospective studies of dose-intense regi-
mens (Table 5). 
However, the result was not as excellent as a clinical trial
reported by Thomas et al. [11]: in the current study, a 
substantial number of patients could not complete 
immunochemotherapy due to toxicities or impaired PS, 
including six episodes of TRM (14.0%). It is contrast to the
patient characteristics of study by Thomas et al. [11], in
which the patients were relatively younger (median age, 46
years), including three patients (9.7%) with a resected 
disease, and in particular, there were no patients with an
ECOG PS of 3 or 4. These results imply that the treatment
outcome of R-hyper-CVAD can be affected by patient 
suitability for dose-intense chemotherapy. Similar findings
were also reported in a recent population-based analysis of
3,691 patients [7]. In that study, which was outside the 
context of clinical trials, the Surveillance Epidemiology and
End Results (SEER) data analysis estimated time trends for
outcomes of BL in the United States. According to the results,
more effective therapies are needed for older patients with
BL despite improvements in survival from the 1973-2001 era
to 2002-2008 era [7].
To escape early death, excellent supportive care is essen-
tial. Considering an incidence of febrile neutropenia of over
90% with five episodes of death due to bacterial septic shock
in the current study, as well as frequent infectious complica-
tions in other studies [5,10,11,18,20], prophylactic antibiotics
and G-CSF should be utilized [21]. In addition, prophylaxis
with rasburicase can reduce fatal consequences of tumor lysis
syndrome [22]. A gap between DFS and EFS in the current
study strongly suggests that survival could be substantially
improved by reducing early death. Therefore, supportive
care should be strictly and routinely performed.
Despite the fact that higher IPI scores and lower ALCs
were shown to be poor prognostic factors of EFS, their 
significance was lost in terms of DFS. Therefore, they might
be risk factors for fatal complications of dose-intense 
treatment, rather than risk factors for treatment failure. 
However, as the prognostic factors in this study are only 
exploratory, these findings should be interpreted cautiously.
Poorer PS had a significant impact on the unsatisfactory RDIs
of doxorubicin and methotrexate. Concerns regarding 
development of peripheral neuropathy and cerebellar ataxia
might mitigate the effect of poor PS on the reduced RDIs of
vincristine and cytarabine. Overall, poor PS seems to keep
patients from maintaining an adequate RDI of several drugs. 
Since treatment of acute lymphoblastic leukemia is 
determined according to a patient’s age (adults vs. young
and adolescents) due to tolerability of the protocols [23], a
similar question may be raised in the case of BL. It is 
reasonable to question whether or not a particular treatment
protocol is as suitable for patients in their 20s as those 
applied to patients older than 60. Considering that age was
one of the independent prognostic factors in the current
study, R-hyper-CVAD might not be an optimal treatment for
elderly patients. However, in our study, there were no 
significant differences in RDI or number of days required for
a complete cycle of R-hyper-CVAD according to age. These
results suggest that some elderly patients can tolerate 
R-hyper-CVAD well. A review article in 2009 on treatment
of adult patients with BL [24] concluded that a part of 
patients over 40 years of age could have highly favorable 
outcomes to modern dose-intense, multi-agent chemother-
apy. Their conclusion is also in line with a previous study on
R-hyper-CVAD in BL by Thomas et al. [11], in which nine of
31 patients (29%) were  60 years, and all were in continuous
CR except for only one episode of later death due to 
infection. Therefore, selection of patients according to
chronological age seems not to be an ideal strategy. Instead,
other tools such as comprehensive geriatric assessment can
be performed in patients with BL or Burkitt-like lymphoma
in the future.
For those who are clearly intolerant to dose-intense 
regimens, alternative therapeutic strategies should be
sought. A recent uncontrolled prospective study conducted
by Dunleavy et al. [25] reported that lower-dose, short-
course chemotherapy consisting of infused etoposide, dox-
orubicin, and cyclophosphamide along with vincristine,
prednisone, plus a double dose of rituximab (SC-EPOCH-
RR) showed promising outcomes among 11 patients with
HIV-associated BL. In that study, 100% progression-free 
survival and 90% OS were achieved after a median follow-
up time of 73 months, and toxicities were manageable. 
Although patients receiving SC-EPOCH-RR were older 
(median age, 44 years vs. 25 years; p=0.03) than the 19 
patients treated with standard dose-adjusted EPOCH-R, and
patients receiving SC-EPOCH-RR also showed poorer PS
(55% vs. 16% of patients with ECOG PS  2, p=0.04), the 
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outcomes were comparable [25]. Therefore, focusing on 
exposure-concentration time of drugs rather than peak con-
centration can be a reasonable strategy, and future studies
are warranted, especially in a subgroup of patients who are
not suitable for dose-intense chemotherapy.
Although the activity of rituximab has been demonstrated
in most B-cell malignancies, data on the role of rituximab in
BL or BL-U are limited. Two phase II studies [10,11] and 
several retrospective studies [18,20] have demonstrated that
rituximab contributes to the improvement of OS in patients
with BL or Burkitt-like lymphoma. A retrospective popula-
tion-based study compared OS between patients on ritux-
imab (n=111) to those without rituximab therapy (n=52), and
according to their univariate analysis, addition of rituximab
confirmed an association with improved OS, mainly in the
cohort of patients aged 40-65. However, when adjusted for
age and chemotherapy regimen, this association failed to
maintain significance [8]. Compared to the MD Anderson
study, a lower dose of rituximab was administered in the
current study due to limitations in national insurance cover-
age, which might have an impact on outcomes. However,
upon assessing the results of previous studies with or with-
out rituximab, the role of rituximab does seems to be, at least,
not absolute. Rather, more refined patient selection, maxi-
mization of supportive care, and efforts to improve dose 
intensity are more important considerations and future 
efforts should focus on how to solve these problems. 
Since we did not conduct a central pathologic review and
did not analyze outcomes according to fluorescence in situ
hybridization due to the scarcity of tested patients, other
high-grade mature B-cell lymphomas such as DLBCL 
may be included in this patient population, and the poor
prognosis of double-hit B-cell lymphoma may not be 
reflected, which is an obvious weakness of this study.
Notwithstanding, we believe that our assertion on the 
limitation of R-hyper-CVAD in terms of toxicity and its 
resultant insufficient dose intensity in certain frail patients is
still appropriate.
Conclusion
R-hyper-CVAD is an effective treatment regimen for
highly aggressive B-cell lymphomas such as BL. However,
due to its significant toxicity and unsatisfactory RDI among
more frail Korean patients, a more tolerable regimen with
preserved efficacy is required for frail patients with BL or
Burkitt-like lymphomas, even in the rituximab era.
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